UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 25, 2015
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-35443
|
56-2110007
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
4233 Technology Drive
Durham, North Carolina 27704
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (919) 287-6300
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events
On February 25, 2015, the Board of Directors (the “Board”) of Argos Therapeutics, Inc. (the “Company”), appointed Philippe van Holle as a member of the audit committee of the Board (the “Audit Committee”), effective immediately. Mr. van Holle will replace Brian Underdown on the Audit Committee. Mr. Underdown will continue to serve as the chairman of the compensation committee of the Board and as a member of the nominating and governance committee of the Board.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ARGOS THERAPEUTICS, INC. | |||
| By: | /s/ Jeffrey D. Abbey | ||
| Name: | Jeffrey D. Abbey | ||
| Title: | President and Chief Executive Officer | ||
DATED: March 4, 2015